Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis

被引:115
作者
Kotzin, BL
Falta, MT
Crawford, F
Rosloniec, EF
Bill, J
Marrack, P
Kappler, J
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Clin Immunol, Dept Med, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Biochem Biophys & Genet, Denver, CO 80262 USA
[4] Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA
[5] Univ Tennessee, Vet Affairs Med Ctr, Memphis, TN 38163 USA
[6] Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA
[7] Univ Tennessee, Dept Med, Memphis, TN 38163 USA
[8] Natl Jewish Med & Res Ctr, Howard Hughes Med Inst, Div Basic Immunol, Denver, CO 80206 USA
关键词
D O I
10.1073/pnas.97.1.291
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Considerable evidence indicates that CD4(+) T cells are important in the pathogenesis of rheumatoid arthritis (RA), but the antigens recognized by these T cells in the joints of patients remain unclear. Previous studies have suggested that type II collagen (CII) and human cartilage gp39 (HCgp39) are among the most likely synovial antigens to be involved in T cell stimulation in RA. Furthermore, experiments have defined dominant peptide determinants of these antigens when presented by HLA-DR4 the most important RA-associated HLA type. We used fluorescent, soluble peptide-DR4 complexes (tetramers) to detect synovial CD4(+) T cells reactive with CII and HCgp39 in DR4(+) patients. The CII-DR4 complex bound in a specific manner to CII peptide-reactive T cell hybridomas, but did not stain a detectable fraction of synovial CD4(+) cells. A background percentage of positive cells (<0.2%) was not greater in DR4 (DRB1*0401) patients compared with those without this disease-associated allele, Similar results were obtained with the gp39-DR4 complex for nearly all RA patients. In a small subset of DR4(+) patients, however, the percentage of synovial CD4(+) cells binding this complex was above background and could not be attributed to nonspecific binding. These studies demonstrate the potential for peptide-MHC class II tetramers to be used to track antigen-specific T cells in human autoimmune diseases. Together, the results also suggest that the major oligoclonal CD4(+) T cell expansions present in RA joints are not specific for the dominant CII and HCgp39 determinants.
引用
收藏
页码:291 / 296
页数:6
相关论文
共 32 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]  
BANERJEE S, 1988, CLIN EXP RHEUMATOL, V6, P373
[4]  
Bieganowska K, 1999, J IMMUNOL, V162, P1765
[5]   Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo [J].
Callan, MFC ;
Tan, L ;
Annels, N ;
Ogg, GS ;
Wilson, JDK ;
O'Callaghan, CA ;
Steven, N ;
McMichael, AJ ;
Rickinson, AB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (09) :1395-1402
[6]  
Cope AP, 1999, ARTHRITIS RHEUM, V42, P1497, DOI 10.1002/1529-0131(199907)42:7<1497::AID-ANR25>3.0.CO
[7]  
2-#
[8]   Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes [J].
Crawford, F ;
Kozono, H ;
White, J ;
Marrack, P ;
Kappler, J .
IMMUNITY, 1998, 8 (06) :675-682
[9]  
Falta MT, 1998, PROG INFLAM RES, P201
[10]   Specificity of an HLA-DRB1*0401-restricted T cell response to type II collagen [J].
Fugger, L ;
Rothbard, JB ;
SonderstrupMcDevitt, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (04) :928-933